Vascular hypertrophy in hypertension: Role of the renin-angiotensin system

Mount Sinai Journal of Medicine

Volumn 65, Issue 2, 1998, Pages 108-117

  Rosendorff, Clive ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

ACE inhibitor; Angiotensin; Angiotensin receptor; Angiotensin converting enzyme; Artery; Hypertension; Losartan; Renin; Vascular hypertrophy

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PERINDOPRIL;

APOPTOSIS; ARTERY COMPLIANCE; ATHEROGENESIS; BLOOD VESSEL TONE; CELL GROWTH; CELL HYPERPLASIA; CELL PROLIFERATION; EXTRACELLULAR MATRIX; HEREDITARY HYPERTENSION; HUMAN; HYPERTENSION; HYPERTROPHY; METABOLISM; MITOGENESIS; NONHUMAN; POLYPLOIDY; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD VESSELS; CELL DIVISION; HUMANS; HYPERTENSION; HYPERTROPHY; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 0031911705     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Gibbons GH, Dzau VJ. Angiotensin converting enzyme inhibition and vascular hypertrophy. Cardiovasc Drugs Ther 1990; 4:237-242.
2. Dzau VJ. Vascular renin-angiotensin system and vascular protection. J Cardiovasc Pharmacol 1993; 22(Suppl 5):S1-S9.
3. Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol 1996; 28:803-812.
4. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation 1993; 87:1816-1828.
5. Samani JN, Swales JD. Molecular biology of the vascular renin-angiotensin system. Blood Vessels 1991; 28:210-216.
6. Ekker M, Tronik D, Rougeon R. Extrarenal transcription of the renin genes in multiple tissues of mice and rats. Proc Natl Acad Sci USA 1989; 86:5155-5158.
7. McGiff JC, Terragano NA, Malik KU, Lonigro AJ. Release of a prostaglandin E-like substance from canine kidney by bradykinin. Circ Res 1972; 31:36-43.
8. Desta B, Vanhoutte PM, Boulanger CM. Inhibition of the angiotensin converting enzyme by perindoprilat and release of nitric oxide. Am J Hypertens 1995; 8:S1-S6.
9. Rosendorff C, Knapp C. The role of autocoids in the pathogenesis of cough induced by angiotensin converting enzyme inhibitors. Cardiology 1993; 82(Suppl 2): 66-71.
10. Okamura R, Myazaki M, Inagami T, Toda N. Vascular renin angiotensin system in two kidney, one clip hypertensive rats. Hypertension 1986; 8:560-565.
11. Morishita R, Higaki J, Okunkishi H, et al. Changes in gene expression of the renin angiotensin system in two kidney, one clip hypertensive rats. J Hypertens 1991; 9:187-192.
12. Jandeleit K, Perich R, Jackson B, Johnston CI. Mesenteric resistance and brain microvascular angiotensin converting enzyme in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol 1992; 19:348-352.
13. Perich R, Jackson B, Paxton D, Johnston CI. Characterization of angiotensin converting enzyme in isolated cerebral microvessels from spontaneously hypertensive and normotensive rats. J Hypertens 1992; 101: 149-153.
14. Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens 1993; 11(Suppl 3):S13-S18.
15. Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept 1993; 43:1-20.
16. Inagami T, Guo DF, Kitami Y. Molecular biology of angiotensin II receptors: an overview. J Hypertens 1994; 12(Suppl 10):S83-S94.
17. de Gasparo M, Husain A, Alexander W, et al. Proposed update of angiotensin receptor nomenclature. Hypertension 1995; 25:924-927.
18. 2 receptors in the developing rat fetus. J Clin Invest 1991; 88:921-933.
19. Viswanathan M, Tsutsumi K, Correa FM, Saavedra JM. Changes in expression of angiotensin receptor subtypes in the rat aorta during development. Biochem Biophys Res Commun 1991; 179:1361-1367.
20. 2 angiotensin II receptor subtypes in the rat brain during development. Proc Natl Acad Sci USA 1991; 88:11440-11444.
21. Janiak P, Pillon A, Prost JF, Vilaine JP. Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension 1992; 20:737-745.
22. Kambayashi Y, Bardham S, Inagami T. Peptide growth factors markedly decrease the ligand binding of angiotensin II type 2 receptor in rat cultured vascular smooth muscle cells. Biochem Biophys Res Commun 1993; 194:478-482.
23. Berridge MJ. Inositol trisphosphate and diacylglycerol: two interacting second messengers. Annu Rev Biochem 1987; 56:159-183.
24. Rogers TB, Lokuta AJ. Angiotensin II signal transduction pathways in the cardiovascular system. Trends Cardiovasc Med 1994; 4:110-116.
25. 2+ mobilization and protein kinase C activation. J Biol Chem 1989; 264:526-530.
26. Duff JL, Marrero MB, Paxton WE, et al. Angiotensin II signal transduction and the mitogen-activated protein kinase pathway. Cardiovasc Res 1995; 30:511-517.
27. Marrero MB, Schieffer B, Paxton WG, et al. The role of tyrosine phosphorylation in angiotensin II-mediated intracellular signaling. Cardiovasc Res 1995; 30:530-536.
28. Duff JL, Berk BC. Angiotensin II-mediated signal transduction events in vascular smooth muscle cells: kinases and phophatases. Blood Press Suppl 1995; 2:55-60.
29. Liao D-F, Duff JL, Daum G, et al. Angiotensin II stimulates MAP kinase kinase kinase activity in vascular smooth muscle cells. Circ Res 1996; 79:1007-1014.
30. Zou Y, Komuro I, Yamazaki T, et al. Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. J Biol Chem 1996; 271:33592-33597.
31. Schieffer B, Marrero MB. Coactivation of the MAP-kinase cascade and the JAK-Stat pathway is necessary for angiotensin II mediated smooth muscle proliferation [abstract]. Circulation 1996; 94(8):I-523.
32. Owens GK. Determinants of angiotensin II induced hypertrophy versus hyperplasia in vascular smooth muscle. Drug Dev Res 1993; 29:83-87.
33. Geisterfer AT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988; 62:749-756.
34. Resink TJ, Scott-Burden T, Baur U, Bühler FR. Increased proliferation rate and phosphoinositide turnover in cultured smooth muscle cells from spontaneously hypertensive rats. J Hypertens 1987; 5:S145-S148.
35. Paguet J-L, Baudouin-Legros M, Brunelle G, Meyer P. Angiotensin II induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 1990; 8:565-572.
36. Korsgaard N, Mulvany MJ. Cellular hypertrophy in mesenteric resistance vessels from renal hypertensive rats. Hypertension 1988; 12:162-167.
37. Mulvany MJ. Control of vascular structure. Am J Med 1993; 94(Suppl 4A):S20-S23.
38. Mulvany MJ, Baandrup U, Gundersen HJG. Evidence for hyperplasia in mesenteric resistance vessels of spontaneously hypertensive rats using a 3-dimensional dissector. Circ Res 1985; 57:794-800.
39. Thybo NK, Korsgaard N, Mulvany MJ. Morphology and function of mesenteric resistance arteries in transgenic rats with low renin hypertension. J Hypertens 1992; 10:1191-1196.
40. Baumbach G, Heistad DD. Remodeling of cerebral arterioles in chronic hypertension. Hypertension 1989; 13: 968-972.
41. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs hyperplasia. J Clin Invest 1992; 90:456-461.
42. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83:1419-1424.
43. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 1996; 93(1):156-160.
44. 2 receptor mediated inhibition of particulate guanilate cyclase: a link with protein tyrosine phosphatase stimulation? Receptors Channels 1994; 2(2):79-87.
45. Hahn AW, Kern F, Bühler FR, Resink TJ. The renin angiotensin system and extracellular matrix. Clin Invest 1993; 71(Suppl 5):S7-S12.
46. 1 receptors. J Clin Invest 1995; 96(1):141-149.
47. Hahn AW, Jonas U, Bühler FR, Resink TJ. Activation of human peripheral monocytes by angiotensin II. FEBS Lett 1994; 347:178-180.
48. Van Leeuwen RTJ, Kol A, Andreotti F, et al. Angiotensin II increases plasminogen inhibitor type 1 and tissue type plasminogen activator messenger RNA in culture rat aortic smooth muscle cells. Circulation 1994; 90: 362-368.
49. Ridker PM, Gaboury CL, Conlin PR, et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin angiotensin system fibrinolytic function. Circulation 1993; 87:1969-1973.
50. Lever AF. Slow pressor mechanisms in hypertension: a role for hypertrophy of resistance vessels? J Hypertens 1986; 4:515-524.
51. Katz AM. Angiotensin II: hemodynamic regulator or growth factor? J Mol Cell Cardiol 1990; 22:739-747.
52. Folkow B. "Structural factor" in primary and secondary hypertension. Hypertension 1990; 16:89-101.
53. Levy BI, Michel J-B, Salzmann J-L, et al. Arterial effects of angiotensin-converting enzyme inhibition in renovascular and spontaneously hypertensive rats. J Hypertens 1988; 6(Suppl 3):S23-S25.
54. Levy BI, Michel J-B, Salzmann J-L, et al. Effects of chronic inhibition of converting enzyme on mechanical and structural properties of arteries in rat renovascular hypertension. Circ Res 1988; 63:227-239.
55. Lee RMKW, Berecek KH, Tsoporis J, et al. Prevention of hypertension and vascular changes by captopril treatment. Hypertension 1991; 17:141-150.
56. Levy BI, Safar ME. Remodeling of the vascular system in response to hypertension and drug therapy. Clin Exp Pharmacol Physiol 1992; S19:33-37.
57. Clozel J-P, Kuhn H, Hefti F. Vascular protection with cilazapril in hypertension. J Cardiovasc Pharmacol 1992; 19(Suppl 5):S28-S33.
58. Sen S, Smeby RR, Bumpus FM. Renin in rats with spontaneous hypertension. Circ Res 1972; 31:876-880.
59. Shiono K, Sokabe H. Renin-angiotensin system in spontaneously hypertensive rat. Am J Physiol 1976; 23: 1295-1299.
60. Smeda JS, Lee RM, Forrest JB. Prenatal and postnatal hydralazine treatment does not prevent renal vessel wall thickening in SHR despite the absence of hypertension. Circ Res 1988; 63:534-542.
61. Owens GK. Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension 1987; 9: 178-187.
62. Christensen KL, Jespersen LT, Mulvany MJ. Development of blood pressure in spontaneously hypertensive rats after withdrawal of long term treatment related to vascular structure. J Hypertens 1989; 7:83-90.
63. Hajdu MA, Heistad DD, Ghoneim S, Baumbach GL. Effects of antihypertensive treatment on composition of cerebral arterioles. Hypertension 1991; 18(Suppl II):II-15-21.
64. Frohlich ED, Horinaka S. Cardiac and aortic effects of angiotensin converting enzyme inhibitors. Hypertension 1991; 18(Suppl II):II-2-7.
65. Linz W, Gohlke P, Unger T, Schölkens BA. Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction. Arch Mal Coeur 1995; 88(II):31-34.
66. Schiffrin EL, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries in hypertensive patients after 2 years of treatment with an angiotensin I converting enzyme inhibitor. Am J Hypertens 1995; 8:229-236.
67. Thybo NK, Stephens N, Cooper A, et al. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995; 25:474-481.
68. Simon AC, Levenson J, Maarek BC, Bouthier JD. Hemodynamic basis of early modifications of the large arteries in borderline hypertension. J Hypertens 1987; 5:179-184.
69. Simon AC, Safar MD, Levenson JA, et al. An evaluation of large arteries compliance in man. Am J Physiol 1979; 237:H550-H554.
70. Messerli FH, Ventura H, Aristimuno GG, et al. Arterial compliance in systolic hypertension. Clin Exp Hypertens 1982; 4:1037-1044.
71. Levenson J, Le Quan Sang KH, Devynck MA, et al. The role of antihypertensive drugs in counteracting adverse influences on large arteries. Am Heart J 1987; 114:992-997.
72. Safar ME, Bouthier JA, Levenson JA, Simon AC. Peripheral large arteries and the response to antihypertensive treatment. Hypertension 1993; 5(Suppl III):III-63-68.
73. Safar ME, Levy BI. The effect of hypertension and ACE inhibition on arterial structure and compliance. Clin Exp Pharmacol Physiol 1992; 19(Suppl 19):29-32.
74. Simon AC, Levenson J, Chau NP, Pithos-Merli I. Role of arterial compliance in the physiopharmacological approach to human hypertension. J Cardiovasc Pharmacol 1992; 19(Suppl 5):S11-S20.
75. Asmar RG, Pannier B, Santoni JP, et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988; 78:941-950.
76. Kool MJ, Lustermans FA, Breed JG, et al. The influence of perindopril and the diuretic combination of amiloride + hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients. J Hypertens 1995; 13:839-848.
77. Levenson JA, Simon AC, Safar ME, et al. Large arteries in hypertension: acute effect of a new calcium entry blocker, nitrendipine. J Cardiovasc Pharmacol 1984; 6(Suppl 7):S1006-S1010.
78. Levenson JA, Simon AC, Bouthier JD, et al. The effect of acute and chronic nicardipine therapy on forearm arterial hemodynamics in essential hypertension. Br J Clin Pharmacol 1985; 20(Suppl):S107-S113.
79. Levenson JA, Simon AC, Bouthier JD, et al. Postsynaptic alpha blockade and brachial artery compliance in essential hypertension. J Hypertens 1984; 2:37-41.
80. Chau NP, Pithois-Merli I, Levenson J, Simon A. Comparative haemodynamic effects of ketanserin and ritanserin in the proximal and distal upper limb circulations of hypertensive patients. Eur J Clin Pharmacol 1989; 37:315-320.
81. Achimastos A, Girerd X, Simon AC, et al. The efficacy of a transdermal formulation of clonidine in mild to moderate hypertension and its effects on the arterial and venous vasculature of the forearm. Eur J Clin Pharmacol 1987; 33:111-114.
82. Perret F, Mooser V, Hayoz D, et al. Evaluation of arterial compliance. Effects of antihypertensive drugs. Hypertension 1991; 18(Suppl II):II-77-83.
83. Hayoz D, Nussberger J, Waeber B, Brunner HR. The renin-angiotensin system and arterial wall behaviour. J Cardiovasc Pharmacol 1993; 22(Suppl 5):S48-S52.
84. Svensson A, Gudbrandsson T, Sivertsson R, Hansson L. Hemodynamic effects of metoprolol and pindolol: a comparison in hypertensive patients. Br J Clin Pharmacol 1982; 13:S259-S267.
85. Gretzer I, Dunér H, Lagerbäck B. Haemodynamic effects of pindolol in essential hypertension with special reference to resistance vessels in the forearm during maximal vasodilatation. J Hypertens 1985; 3(Suppl 3): 8215-8217.
86. Agabiti-Rosei E, Muiesan ML, Geri A, et al. Long-term antihypertensive treatment may induce normalization of left ventricular mass before complete regression of vascular structural changes: consequences for cardiac function at rest and during stress. J Hypertens 1988; 6(Suppl 4):S94-S96.
87. Dahlöf B, Hansson L. The influence of antihypertensive therapy on the structural arteriolar changes in essential hypertension: different effects of enalapril and hydrochlorothiazide. J Intern Med 1993; 234:271-279.
88. Girerd X, Moulin C, Boutouyrie P, et al. Normalization of the elastic modulus of large artery wall material by long term treatment in elderly hypertensives [abstract]. Hypertension 1995; 26(3):560.
89. Safar ME, Girerd X, Laurent S. Structural changes of large conduit arteries in hypertension. J Hypertension 1996; 14:545-555.
90. Stumpe KO, Ludwig M, Heagerty AM, et al. Vascular wall thickness in hypertension: the Perindopril Regression of Vascular Thickening European Community Trial: PROTECT. Am J Cardiol 1995; 76(15):50E-54E.
91. Chiu AT, Roscoe WA, McCall DE, Timmermans PB. Angiotensin II-1 receptors mediate both vasoconstrictor and hypertrophic responses in rat aortic smooth muscle cells. Receptor 1991; 1:133-140.
92. Millet D, Desgranges C, Campan M, et al. Effects of angiotensins on cellular hypertrophy and c-fos expression in cultured arterial smooth muscle cells. Eur J Biochem 1992; 206:367-372.
93. Sachinidis A, Ko Y, Weisser P, et al. EXP31754, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells. J Hypertens 1993; 11:155-162.
94. 1 receptor. J Hypertens 1992; 10: 1463-1469.
95. Ko Y, Gor A, Appenheimer M, et al. Losartan inhibits the angiotensin II-induced stimulation of the phosphoinositide signaling system in vascular smooth muscle cells. Eur J Pharmacol 1992; 227:215-219.
96. Oddie CJ, Dilley RJ, Kanellakis P, Bobik A. Chronic angiotensin II type 1 receptor antagonism in genetic hypertension: effects on vascular structure and reactivity. J Hypertens 1993; 11:717-724.
97. Soltis EE. Alterations in vascular structure and function after short-term losartan treatment in spontaneously hypertensive rats. J Pharmacol Exp Ther 1993; 266: 642-646.
98. Morton JJ, Beattie EC, MacPherson F. Angiotensin II receptor antagonist losartan has persistent effects on blood pressure in the young spontaneously hypertensive rat: lack of relation to vascular structure. J Vasc Res 1992; 29:264-269.
99. Shaw LM, George PR, Oldham AA, Heagerty AM. A comparison of the effect of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism on the structural changes associated with hypertension in rat small arteries. J Hypertens 1995; 13:1135-1143.
100. Vacher E, Richer C, Giudicelli J-F. Effects of losartan on cerebral arteries in stroke-prone spontaneously hypertensive rats. J Hypertens 1996; 14:1341-1348.
101. Morishita R, Gibbons GH, Ellison EK, et al. Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. J Clin Invest 1994; 94:978-984.
102. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9:342-360.